ASX - By Stock
|
ILA |
Re:
Ann: Investor Presentation - Asia Bio Partnering
|
|
Investie
|
17 |
2.0K |
2 |
13:26 |
13:26 |
ASX - By Stock
|
17
|
2.0K
|
2
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Investor Presentation - Asia Bio Partnering
|
|
Investie
|
17 |
2.0K |
1 |
13:11 |
13:11 |
ASX - By Stock
|
17
|
2.0K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Investor Presentation - Asia Bio Partnering
|
|
Investie
|
17 |
2.0K |
0 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
17
|
2.0K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials
|
|
Investie
|
1 |
374 |
0 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
1
|
374
|
0
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Security Class Reinstatement to Quotation ILAO
|
|
Investie
|
8 |
1.2K |
0 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
8
|
1.2K
|
0
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Security Class Reinstatement to Quotation ILAO
|
|
Investie
|
8 |
1.2K |
0 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
8
|
1.2K
|
0
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Security Class Reinstatement to Quotation ILAO
|
|
Investie
|
8 |
1.2K |
1 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
8
|
1.2K
|
1
|
|
ASX - By Stock
|
COV |
Re:
Ann: CLEO Appoints Partner to Commence U.S. Market Access Program
|
|
Investie
|
2 |
559 |
2 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
2
|
559
|
2
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Results of Rights Issue Offer
|
|
Investie
|
21 |
4.2K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
21
|
4.2K
|
0
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Results of Rights Issue Offer
|
|
Investie
|
21 |
4.2K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
21
|
4.2K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: Peer-Review Supports CLEOs Ovarian Cancer Detection Tech
|
|
Investie
|
1 |
385 |
2 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
1
|
385
|
2
|
|
ASX - By Stock
|
AVR |
Re:
AVR results presentation at CRT 24 Washington DC 9th to 12th March
|
|
Investie
|
65 |
23K |
2 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
65
|
23K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
AVR results presentation at CRT 24 Washington DC 9th to 12th March
|
|
Investie
|
65 |
23K |
5 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
65
|
23K
|
5
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Results of Rights Issue Offer
|
|
Investie
|
21 |
4.2K |
1 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
21
|
4.2K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Results of Rights Issue Offer
|
|
Investie
|
21 |
4.2K |
0 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
21
|
4.2K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: Appendix 4D and Half Yearly Accounts
|
|
Investie
|
1 |
388 |
0 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
1
|
388
|
0
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Results of Rights Issue Offer
|
|
Investie
|
21 |
4.2K |
0 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
21
|
4.2K
|
0
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Results of Rights Issue Offer
|
|
Investie
|
21 |
4.2K |
4 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
21
|
4.2K
|
4
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Despatch of Rights Issue documentation
|
|
Investie
|
17 |
2.7K |
1 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
17
|
2.7K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: $1.95million Fully Underwritten Rights Issue
|
|
Investie
|
22 |
5.2K |
2 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
22
|
5.2K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
AVR results presentation at CRT 24 Washington DC 9th to 12th March
|
|
Investie
|
65 |
23K |
15 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
65
|
23K
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Ann: DAYBUE net sales US$87.1 million in Q4 2023
|
|
Investie
|
79 |
36K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
79
|
36K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
Investie
|
422 |
188K |
6 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
422
|
188K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: DAYBUE net sales US$87.1 million in Q4 2023
|
|
Investie
|
79 |
36K |
4 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
79
|
36K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: DAYBUE net sales US$87.1 million in Q4 2023
|
|
Investie
|
79 |
36K |
5 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
79
|
36K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: DAYBUE net sales US$87.1 million in Q4 2023
|
|
Investie
|
79 |
36K |
9 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
79
|
36K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
price control
|
|
Investie
|
13 |
6.4K |
3 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
13
|
6.4K
|
3
|
|
ASX - By Stock
|
ILA |
Re:
Ann: $1.95million Fully Underwritten Rights Issue
|
|
Investie
|
22 |
5.2K |
4 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
22
|
5.2K
|
4
|
|
ASX - By Stock
|
ILA |
Re:
Ann: $1.95million Fully Underwritten Rights Issue
|
|
Investie
|
22 |
5.2K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
22
|
5.2K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: $1.95million Fully Underwritten Rights Issue
|
|
Investie
|
22 |
5.2K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
22
|
5.2K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: $1.95million Fully Underwritten Rights Issue
|
|
Investie
|
22 |
5.2K |
0 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
22
|
5.2K
|
0
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Trading Halt
|
|
Investie
|
8 |
1.6K |
2 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
8
|
1.6K
|
2
|
|
ASX - By Stock
|
COV |
Re:
Ann: Results of Annual General Meeting
|
|
Investie
|
3 |
1.6K |
1 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
3
|
1.6K
|
1
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Investie
|
1.6K |
823K |
2 |
23/02/24 |
23/02/24 |
Charts
|
1.6K
|
823K
|
2
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Trading Halt
|
|
Investie
|
8 |
1.6K |
1 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
8
|
1.6K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Trading Halt
|
|
Investie
|
8 |
1.6K |
3 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
8
|
1.6K
|
3
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Third cohort dosed in ISLA-101 Single Ascending Dose study
|
|
Investie
|
11 |
1.9K |
1 |
21/01/24 |
21/01/24 |
ASX - By Stock
|
11
|
1.9K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Third cohort dosed in ISLA-101 Single Ascending Dose study
|
|
Investie
|
11 |
1.9K |
2 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
11
|
1.9K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Investor Presentation
|
|
Investie
|
66 |
20K |
1 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
66
|
20K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Further Update on Edwards
|
|
Investie
|
200 |
55K |
0 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
200
|
55K
|
0
|
|
ASX - By Stock
|
COV |
Re:
Ann: Results of Annual General Meeting
|
|
Investie
|
3 |
1.6K |
2 |
15/01/24 |
15/01/24 |
ASX - By Stock
|
3
|
1.6K
|
2
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Approval to commence dosing 3rd cohort of ISLA-101 SAD study
|
|
Investie
|
15 |
3.4K |
3 |
13/01/24 |
13/01/24 |
ASX - By Stock
|
15
|
3.4K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Update on Equity Raising
|
|
Investie
|
28 |
9.9K |
1 |
17/12/23 |
17/12/23 |
ASX - By Stock
|
28
|
9.9K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Update on Equity Raising
|
|
Investie
|
28 |
9.9K |
3 |
16/12/23 |
16/12/23 |
ASX - By Stock
|
28
|
9.9K
|
3
|
|
ASX - By Stock
|
ILA |
Re:
Ann: R&D Tax Incentive loan facility secured with Radium Capital
|
|
Investie
|
7 |
1.8K |
4 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
7
|
1.8K
|
4
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Second cohort dosed in ISLA-101 Single Ascending Dose study
|
|
Investie
|
6 |
1.0K |
2 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
6
|
1.0K
|
2
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Second cohort dosed in ISLA-101 Single Ascending Dose study
|
|
Investie
|
6 |
1.0K |
4 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
6
|
1.0K
|
4
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Completion of Entitlement Offer
|
|
Investie
|
23 |
7.6K |
2 |
08/12/23 |
08/12/23 |
ASX - By Stock
|
23
|
7.6K
|
2
|
|
ASX - By Stock
|
ILA |
Re:
ILA - Media coverage
|
|
Investie
|
12 |
2.3K |
1 |
08/12/23 |
08/12/23 |
ASX - By Stock
|
12
|
2.3K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
ILA - Media coverage
|
|
Investie
|
12 |
2.3K |
0 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
12
|
2.3K
|
0
|
|